Section ofEndocrinology 655 92 % and the average litter size at three weeks of pregnancy was 9-5 which was similar to that obtained in animals untreated with gonadotrophins. Such techniques permit exact planning of a breeding programme and offer new possibilities for controlled animal production.
Pergonal is a human urinary gonadotrophin preparation which has a potency of 75 i.u. FSH per ampoule. As with other FSH preparations which are used to induce follicular maturation in infertile women there is a considerable variation in individual dose requirement. We have attempted to consider some of the variables which may affect this dose requirement: (1) What response is required? (2) Is the dose requirement dependent upon clinical diagnosis? (3) Which therapeutic regime is most likely to lead to the required response ?
The answer to the first question is straightforward. The response required is a single ovulation, without hyperstimulation. More specifically the FSH preparation is required to cause maturation of a single follicle. The luteinizing stimulus, usually human chorionic gonadotrophin (HCG), is then used to induce ovulation and corpus luteum formation.
To determine whether the expected dose requirement is dependent on the clinical category of the patient, an analysis has been made of data kindly made available by Professor E M Rabau and Dr B Lunenfeld of Tel-Aviv, Israel. They have given daily injections of Pergonal, varying the dose and the duration of treatment until the patient showed evidence of follicular maturation, as judged by direct or indirect measurements of aestrogenic activity. To ensure that only treatment courses were analysed where the dose was correct, courses which failed to induce ovulation, or which led to clinical hyperstimulation, have been excluded.
We initially considered the possibility that patients may have a higher dose requirement for pregnancy to occur than for ovulation without pregnancy. Individual means were calculated for each patient from courses which were ovulatory only and those where pregnancy occurred, including only patients where both observations were available. From these values overall means were derived for ovulatory cycles and pregnancy cycles:
To induce ovulation without pregnancy (64 observations): 26-8 ampoules To induce ovulation and pregnancy (48 observations): 
ampoules
The difference between these two means is only on the borderline of statistical significance, and greater numbers are needed. For the present it seems fair to say that the actual difference is too small to be of clinical importance. The next step was to calculate the mean doses for each patient from ovulatory cycles, with or without pregnancy. From these individual means, group means were derived to show the dosage requirement in various diagnostic categories (Table 1) .
The various mean dose requirements shown in the righthand column of Table 1 were compared, using a single factor analysis of variance, and the The presence or absence of galactorrhoea does not seem to be related to dose requirement, but the differences between the other groups are statistically highly significant. Fig 1 shows clearly that although the mean doses in the two diagnostic categories are significantly different, there is a considerable range of individual means in each group (approximately 5 to 1) and an overlap between the groups. For this reason, the diagnostic category of the patient will give only some initial guidance to treatment. The need to individualize treatment remains.
The aim of treatment is to reproduce the normal physiological maturation of the follicle and then to give chorionic gonadotrophin as a source of LH activity to induce ovulation and corpus luteum formation. Recent investigations by Fukushima et al. (1964) and other groups into the excretion of FSH and LH during the normal ovulatory cycle have suggested that FSH may be required only for a few days at the beginning of the cycle. In addition we now know that the maximum cestrogenic response occurs five to eight days after a single injection of FSH, or after eleven to twelve days if HCG is combined with the FSH dose. This information has cast doubt upon the rationale of eight to ten day courses of FSH and has prompted Crooke and others to attempt ovulation induction with a single dose of FSH, followed by HCG eight or ten days later. We now know that this is an effective regime and there are good reasons for believing that it may lead to a lower incidence of hyperstimulation including multiple pregnancy. A study of the optimum treatment of infertile amenorrhceic patients with human folliclestimulating hormone (FSH) and chorionic gonadotrophin (HCG) requires the investigation of a number of variables. These include variations between patients, between dosage, number of injections and length of treatment with FSH and the same with HCG and variations in the timing of treatment with HCG in relation to FSH. In our experiments responses were assessed by increases in excretion of cestriol and of pregnanediol using formal statistical designs (Crooke et al. 1963) . Several interesting facts emerged. The best responses occurred with 24,000 i.u. HCG given as a single injection two days after the last dose of FSH. When the total dose of FSH was given as a single injection or divided into 2, 4 or 8 equal injections a good linear relationship between response and number of injections was demonstrated, a single injection being twice as effective
